Skip to main content
. 2020 Jul 16;123(6):982–987. doi: 10.1038/s41416-020-0969-5

Fig. 3. Association of ptDNA dynamics with treatment response.

Fig. 3

a ptDNA change and PSA flare in patient A3. b ptDNA change and bone pseudoprogression in patient A7. Patient A3 is characterised by an initial PSA elevation followed by a PSA decline and no radiographic progression on 18F-fluorocholine positron emission tomography/computed tomography (FCH-PET/CT) by using semiquantitative criteria based on the maximum standardised radiotracer uptake value (SUVmax). Patient A7 showed a bone flare on abiraterone characterised by an early increase in the intensity of bone lesions in the context of treatment response. In both these cases, ptDNA did not follow PSA and radiographic changes, but reduced in the first ~3 months from starting abiraterone.